Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 24.1
edited by manuelmenendez
on 2025/01/29 18:46
Change comment: There is no comment for this version
To version 5.1
edited by manuelmenendez
on 2025/01/27 23:04
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,10 +2,9 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= //A new tridimensional diagnostic framework for CNS diseases// =
5 += Neurodiagnoses =
6 6  
7 -This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8 -We aim to create a structured, interpretable, and scalable diagnostic tool.
7 +This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool.
9 9  )))
10 10  )))
11 11  
... ... @@ -13,70 +13,19 @@
13 13  (((
14 14  (% class="col-xs-12 col-sm-8" %)
15 15  (((
16 -= What is this about and what can I find here? =
15 += What can I find here? =
17 17  
18 -== **Overview** ==
19 -
20 -The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on:
21 -
22 -* **Axis 1**: Etiology (genetic or other causes of diseases).
23 -* **Axis 2**: Molecular Markers (biomarkers).
24 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25 -
26 -
27 -[[For instance, neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
28 -
29 -
30 -This methodology enables:
31 -
32 -* Greater precision in diagnosis.
33 -* Integration of incomplete datasets using AI-driven probabilistic modeling.
34 -* Stratification of patients for personalized treatment.
35 -
36 -== **The case of neurodegenerative diseases** ==
37 -
38 -There have been described these 3 diagnostic axes:
39 -
40 -* (((
41 -**Axis 1: Etiology**
42 -
43 -* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
44 -* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
45 -* //Tests//: Genetic testing, lifestyle, and cardiovascular screening.
46 -)))
47 -* (((
48 -**Axis 2: Molecular Markers**
49 -
50 -* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
51 -* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
52 -* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
53 -)))
54 -* (((
55 -**Axis 3: Neuroanatomoclinical**
56 -
57 -* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
58 -* //Examples//: Hippocampal atrophy correlating with memory deficits.
59 -* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
60 -)))
61 -
62 -== **Applications** ==
63 -
64 -This system enhances:
65 -
66 -* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
67 -* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
68 -
69 69  == Who has access? ==
70 70  
71 71  We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
72 72  
73 -== How to Contribute ==
21 +== How to Contribute: ==
74 74  
75 75  * Access the `/docs` folder for guidelines.
76 76  * Use `/code` for the latest AI pipelines.
77 77  * Share feedback and ideas in the wiki discussion pages.
78 78  
79 -== Key Objectives ==
27 +== Key Objectives: ==
80 80  
81 81  * Develop interpretable AI models for diagnosis and progression tracking.
82 82  * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
... ... @@ -90,14 +90,11 @@
90 90  {{toc/}}
91 91  {{/box}}
92 92  
93 -== Main contents ==
41 +== Main contents: ==
94 94  
95 95  * `/docs`: Documentation and contribution guidelines.
96 96  * `/code`: Machine learning pipelines and scripts.
97 97  * `/data`: Sample datasets for testing.
98 98  * `/outputs`: Generated models, visualizations, and reports.
99 -* [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]]
100 -* [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]]
101 -* [[to-do-list>>to-do-list]]
102 102  )))
103 103  )))
tridimensional.png
Author
... ... @@ -1,1 +1,0 @@
1 -XWiki.manuelmenendez
Size
... ... @@ -1,1 +1,0 @@
1 -149.8 KB
Content
Collaboratory.Apps.Collab.Code.CollabClass[0]
Public
... ... @@ -1,1 +1,1 @@
1 -Yes
1 +No
XWiki.XWikiRights[3]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Levels
... ... @@ -1,1 +1,0 @@
1 -view
Users
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiGuest
XWiki.XWikiRights[4]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Groups
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiAllGroup
Levels
... ... @@ -1,1 +1,0 @@
1 -view